These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 32520675)
1. Advances in Sickle Cell Disease Treatments. Pavan AR; Dos Santos JL Curr Med Chem; 2021; 28(10):2008-2032. PubMed ID: 32520675 [TBL] [Abstract][Full Text] [Related]
2. Red Blood Cells as Therapeutic Target to Treat Sickle Cell Disease. Bhatt S; Argueta DA; Gupta K; Kundu S Antioxid Redox Signal; 2024 Jun; 40(16-18):1025-1049. PubMed ID: 37975291 [No Abstract] [Full Text] [Related]
3. Drug Therapies for the Management of Sickle Cell Disease. Rai P; Ataga KI F1000Res; 2020; 9():. PubMed ID: 32765834 [TBL] [Abstract][Full Text] [Related]
4. Sickle cell disease: progress towards combination drug therapy. Pace BS; Starlard-Davenport A; Kutlar A Br J Haematol; 2021 Jul; 194(2):240-251. PubMed ID: 33471938 [TBL] [Abstract][Full Text] [Related]
5. Potential role of LSD1 inhibitors in the treatment of sickle cell disease: a review of preclinical animal model data. Rivers A; Jagadeeswaran R; Lavelle D Am J Physiol Regul Integr Comp Physiol; 2018 Oct; 315(4):R840-R847. PubMed ID: 30067082 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease. Ferraresi M; Panzieri DL; Leoni S; Cappellini MD; Kattamis A; Motta I Eur J Pediatr; 2023 Jun; 182(6):2509-2519. PubMed ID: 36997768 [TBL] [Abstract][Full Text] [Related]
7. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope? Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920 [TBL] [Abstract][Full Text] [Related]
8. Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review. Dick MH; Abdelgadir A; Kulkarni VV; Akram H; Chatterjee A; Pokhrel S; Khan S Cureus; 2022 May; 14(5):e24920. PubMed ID: 35706735 [TBL] [Abstract][Full Text] [Related]
9. Sickle cell disease: combination new therapies vs. CRISPR-Cas9 potential and challenges - review article. Youssry I; Ayad N Ann Hematol; 2024 Aug; 103(8):2613-2619. PubMed ID: 37867187 [TBL] [Abstract][Full Text] [Related]
13. Sickle Cell Disease: From Genetics to Curative Approaches. Hardouin G; Magrin E; Corsia A; Cavazzana M; Miccio A; Semeraro M Annu Rev Genomics Hum Genet; 2023 Aug; 24():255-275. PubMed ID: 37624668 [TBL] [Abstract][Full Text] [Related]
14. Advances in the Treatment of Sickle Cell Disease. Kapoor S; Little JA; Pecker LH Mayo Clin Proc; 2018 Dec; 93(12):1810-1824. PubMed ID: 30414734 [TBL] [Abstract][Full Text] [Related]
15. Gene Therapy as the New Frontier for Sickle Cell Disease. Garg H; Tatiossian KJ; Peppel K; Kato GJ; Herzog E Curr Med Chem; 2022; 29(3):453-466. PubMed ID: 34047257 [TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Sickle-Cell Disease Therapies: A Review of Voxelotor, Crizanlizumab, and L-glutamine. Migotsky M; Beestrum M; Badawy SM Pharmacy (Basel); 2022 Sep; 10(5):. PubMed ID: 36287444 [TBL] [Abstract][Full Text] [Related]
17. Recent insights on the medicinal chemistry of sickle cell disease. Dos Santos JL; Chin CM Curr Med Chem; 2011; 18(15):2339-58. PubMed ID: 21517749 [TBL] [Abstract][Full Text] [Related]